CSF_axSpA_Highlights_EULAR2022

EULAR 2002
Congress Preview
axSpA
Steering Committee Introduction
Dear CSF Member,
Welcome to this year’s selection of EULAR abstracts on axSpA and my ‘Top Picks’. Within these pages you’ll find 22 abstracts
that we at the CSF think you’ll find interesting.
On Day 1 we have the AxSpA Drug Treatment: New and Old Drugs session, which is packed full of interesting oral presentations
and definitely not one to be missed. Amongst our selections are presentations on upadacitinib (OP0016), ixekizumab (OP0017),
bimekizumab (OP0019) and secukinumab (OP0023), as well as NSAIDs (OP0018 and OP0021) and the impact of sex differences
on TNFi effectiveness (OP0020).
The AxSpA: About Treatments and Outcomes poster session on Day 4 is another must-see. There you’ll find posters on tofacitinib
(POS0296 and POS0305), secukinumab (POS0297, POS0299 and POS0300), ixekizumab (POS0301) and upadacitinib (POS0306).
This year, we’re producing separate highlights brochures for axSpA, PsA and RA, so make sure to go to the Cytokine Signalling
Forum and download our other highlights brochures. If you’re looking for the latest on lupus, head over to
https://www.lupus-forum.com/ where you’ll find their EULAR selections
As always, thank you for your continued support. We hope you have a fantastic time at EULAR 2022 – especially if this is your first
in-person congress for a while!
Kind regards
Professor Atul Deodhar
Key Presentations
Chairman’s Picks
Wednesday, 01 June 2022
All day POSTER VIEW 6
POS0930
POS0931
POS0937
POS0938
POS0939
POS0949
14:15–
15:30
–
Safety and efficacy of ixekizumab treatment in patients with axial spondyloarthritis: 3-year clinical trial results from
the COAST programme
Atul Deodhar
Efficacy and improvement in patient-reported outcomes at weeks 16 and 52 in ixekizumab treated biological naïve
patients with radiographic axial spondyloarthritis achieving clinically important pain at night reduction at week 16:
results from COAST-V trial
Sofia Ramiro
MEASURE 2: Secukinumab provides rapid and sustained relief from key clinical symptoms of active ankylosing
spondylitis in TNFi-naïve patients through 5 years
Karel Pavelka
Maintenance of response to bimekizumab over 3 years of treatment in patients with active ankylosing spondylitis:
post hoc analyses from the BE AGILE study and its open-label extension
Victoria Navarro-Compán
Bimekizumab in patients with active non-radiographic axial spondyloarthritis: 24-week efficacy & safety from
BE MOBILE 1, a phase 3, multicentre, randomised, placebo‐controlled study
Xenofon Baraliakos
No change in serum levels of bone turnover markers corrected for age and gender during the first year of secukinumab
treatment in patients with ankylosing spondylitis
Mark Siderius
EULAR RECOMMENDATIONS SESSION
Update of the ASAS/EULAR recommendations on the management of axial spondyloarthritis
Sofia Ramiro
Register for FREE content at www.cytokinesignalling.com
DEVELOPED UNDER
THE AUSPICES OF THE
Follow us at:
Cytokine Signalling Forum

Chairman’s Picks
16:30–
18:00
OP0016
OP0017
OP0018
OP0019
OP0020
OP0021
OP0023
16:30–
18:00
OP0034
AxSpA DRUG TREATMENT: NEW AND OLD DRUGS
Efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis:
a double-blind, randomized, placebo-controlled phase 3 trial
Filip van den Bosch
Recapture rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis:
results at week 104 from a randomized placebo-controlled withdrawal study
Robert B.M. Landewé
Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on
progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) –
an open-label, randomized controlled, multicenter trial
Fabian Proft
Bimekizumab in patients with active ankylosing spondylitis: 24-week efficacy & safety from BE MOBILE 2,
a phase 3, multicentre, randomised, placebo-controlled study
Désirée van der Heijde
Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis; results from
fifteen countries in the EuroSpA Research Collaboration Network
Pasoon Hellamand
Treatment with non-steroidal anti-inflammatory drugs is associated with retardation of radiographic spinal progression
in patients with axial spondyloarthritis: 10-year results from the GErman SPondyloarthritis Inception Cohort
Murat Torgutalp
A randomized, double-blind trial comparing secukinumab 300 mg and 150 mg at Week 52 in patients with
ankylosing spondylitis who did not achieve inactive disease during an initial 16 weeks of open-label treatment with
secukinumab 150 mg
Marina Magrey
FROM RISK ASSESMENT TO SOCIETAL OUTCOMES
Ixekizumab improves signs, symptoms, and quality of life in patients with axial SpA irrespective of disease duration:
results from the COAST-V, COAST-W and COAST-X trials
Victoria Navarro-Compán
Saturday, 02 June 2022
10:15–
11:45
POS0296
POS0297
POS0299
POS0300
POS0301
POS0305
POS0306
POSTER TOUR AUDITORIUM 6
AxSpA: ABOUT TREATMENTS AND OUTCOMES
Integrated safety analysis of tofacitinib in ankylosing spondylitis clinical trials
Atul Deodhar
Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study
Giacomo Cozzi
Effect of secukinumab on radiographic progression and inflammation in sacroiliac joints and spine in patients with
non-radiographic axial spondyloarthritis: 2-year imaging outcomes from a phase III randomised trial
Juergen Braun
Factors associated with secukinumab (SEC) retention in axial Spondyloarthritis (axSpA): results of the French
retrospective study FORSYA
Maxime Dougados
Structural outcomes in the sacroiliac joint after ixekizumab treatment for 16 weeks in patients with active
non‐radiographic axial spondyloarthritis stratified by gender, HLA-B27, and baseline MRI inflammation
Walter P Maksymowych
Time to improvement of fatigue in patients with ankylosing spondylitis in a study of tofacitinib
Laure Gossec
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy:
a double-blind, randomized, placebo-controlled phase 3 trial
Désirée van der Heijde
SPONSORSHIP AND UNRESTRICTED EDUCATIONAL GRANTS FROM
Register for FREE content at www.cytokinesignalling.com
DEVELOPED UNDER
THE AUSPICES OF THE
Follow us at:
Cytokine Signalling Forum